| |  Online-Ressource |
|---|
| Verfasst von: | Italiano, Antoine [VerfasserIn]  |
|---|
| | Nanda, Shivani [VerfasserIn] |
|---|
| | Briggs, Andrew [VerfasserIn] |
|---|
| | Garcia-Foncillas, Jesus [VerfasserIn] |
|---|
| | Lassen, Ulrik [VerfasserIn] |
|---|
| | Vassal, Gilles [VerfasserIn] |
|---|
| | Kummar, Shivaani [VerfasserIn] |
|---|
| | Tilburg, Cornelis M. van [VerfasserIn] |
|---|
| | Hong, David S. [VerfasserIn] |
|---|
| | Laetsch, Theodore W. [VerfasserIn] |
|---|
| | Keating, Karen [VerfasserIn] |
|---|
| | Reeves, John A. [VerfasserIn] |
|---|
| | Fellous, Marc [VerfasserIn] |
|---|
| | Childs, Barrett H. [VerfasserIn] |
|---|
| | Drilon, Alexander [VerfasserIn] |
|---|
| | Hyman, David M. [VerfasserIn] |
|---|
| Titel: | Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer |
|---|
| Titelzusatz: | an intra-patient comparative analysis |
|---|
| Verf.angabe: | Antoine Italiano, Shivani Nanda, Andrew Briggs, Jesus Garcia-Foncillas, Ulrik Lassen, Gilles Vassal, Shivaani Kummar, Cornelis M. van Tilburg, David S. Hong, Theodore W. Laetsch, Karen Keating, John A. Reeves, Marc Fellous, Barrett H. Childs, Alexander Drilon and David M. Hyman |
|---|
| E-Jahr: | 2020 |
|---|
| Jahr: | 4 November 2020 |
|---|
| Teil: | volume:12 |
|---|
| | year:2020 |
|---|
| | number:11 |
|---|
| Fussnoten: | Gesehen am 08.02.2020 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2020 |
|---|
| Band/Heft Quelle: | 12(2020,11) Artikel-Nummer 3246, 10 Seiten |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Randomized controlled basket trials investigating drugs targeting a rare molecular alteration are challenging. Using patients as their own control overcomes some of these challenges. Growth modulation index (GMI) is the ratio of progression-free survival (PFS) on the current therapy to time to progression (TTP) on the last prior line of therapy; GMI ≥ 1.33 is considered a threshold of meaningful clinical activity. In a retrospective, exploratory analysis among patients with advanced tropomyosin receptor kinase (TRK) fusion cancer treated with the selective TRK inhibitor larotrectinib who received ≥1 prior line of therapy for locally advanced/metastatic disease, we determined the proportion of patients with GMI ≥ 1.33; patients who had not progressed by data cut-off were censored for PFS. Among 72 eligible patients, median GMI was 2.68 (range 0.01-48.75). Forty-seven patients (65%) had GMI ≥ 1.33; 13/25 patients (52%) with GMI < 1.33 had not yet progressed on larotrectinib. Kaplan-Meier estimates showed a median GMI of 6.46. The probability of attaining GMI ≥ 1.33 was 0.75 (95% confidence interval (CI), 0.65-0.85). Median TTP on previous treatment was 3.0 months (95% CI, 2.6-4.4). Median PFS on larotrectinib was not estimable ((NE); 95% CI, NE; hazard ratio, 0.220 (95% CI, 0.146-0.332)). This analysis suggests larotrectinib improves PFS for patients with TRK fusion cancer compared with prior therapy. |
|---|
| DOI: | doi:10.3390/cancers12113246 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.3390/cancers12113246 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/12/11/3246 |
|---|
| | DOI: https://doi.org/10.3390/cancers12113246 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | NTRK gene fusion |
|---|
| | growth modulation index |
|---|
| | larotrectinib |
|---|
| | TRK fusion cancer |
|---|
| | tropomyosin receptor kinase |
|---|
| K10plus-PPN: | 1747793213 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer / Italiano, Antoine [VerfasserIn]; 4 November 2020 (Online-Ressource)
